Molecular Partners

MOLNPhase 2

Zürich, SwitzerlandFounded 2004molecularpartners.com

Molecular Partners AG is a pioneer in the development of DARPin (Designed Ankyrin Repeat Protein) therapeutics, an entirely new class of custom-built protein drugs designed to overcome limitations of conventional biologics. The company leverages its proprietary platform to create multi-specific, logic-gated, and radio-conjugated drug candidates, primarily targeting cancers with high unmet need. Its strategy combines in-house R&D expertise with strategic partnerships to advance a diverse pipeline, including its lead programs MP0533 for AML and MP0712 for solid tumors.

Market Cap

$171.5M

Founded

2004

Focus

Biologics

MOLN · Stock Price

USD 4.5916.40 (-78.16%)

Historical price data

AI Company Overview

Technology Platform

DARPin (Designed Ankyrin Repeat Protein) platform, enabling the design of small, stable, multi-specific protein therapeutics that can be engineered as immune cell engagers, radio-conjugates, or conditionally-active (Switch) molecules.

Pipeline Snapshot

12 drugs in pipeline

Drug	Indication	Stage
ensovibep	Covid19	Phase 2
MP0317 + Gemcitabine + Cisplatine + Durvalumab + Gemcitabine + Cisplatin + Durva...	Advanced Biliary Tract Carcinoma	Phase 2
MP0250 plus BOR+DEX	Multiple Myeloma in Relapse	Phase 1/2
MP0250	Neoplasms	Phase 1/2
MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monothe...	Leukemia	Phase 1/2

Opportunities

Significant opportunities exist in validating the DARPin platform through clinical success, particularly in the high-growth radiopharmaceutical and conditional immunotherapy spaces.

Successful data from lead programs could lead to lucrative partnerships or buyout interest from large pharma seeking next-generation oncology modalities.

Risk Factors

Key risks include clinical failure of lead candidates, which would undermine confidence in the entire DARPin platform; intense competition from established antibody and radiopharmaceutical companies; and the ongoing need to raise capital in volatile markets to fund expensive late-stage trials.

Competitive Landscape

Competes with large pharma and biotechs in multi-specific engagers (e.g., Amgen), radiopharmaceuticals (e.g., Novartis, RayzeBio), and conditional immunotherapy. Differentiation hinges on the DARPin scaffold's potential advantages in design, stability, and tumor penetration over traditional antibodies.